Cargando…
Early Abrogation of Gelatinase Activity Extends the Time Window for tPA Thrombolysis after Embolic Focal Cerebral Ischemia in Mice
Acute ischemic stroke (AIS) is caused by clotting in the cerebral arteries, leading to brain oxygen deprivation and cerebral infarction. Recombinant human tissue plasminogen activator (tPA) is currently the only Food and Drug Administration-approved drug for ischemic stroke. However, tPA has to be a...
Autores principales: | Chen, Shanyan, Chen, Zhenzhou, Cui, Jiankun, McCrary, Myah L., Song, Hailong, Mobashery, Shahriar, Chang, Mayland, Gu, Zezong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021166/ https://www.ncbi.nlm.nih.gov/pubmed/29963617 http://dx.doi.org/10.1523/ENEURO.0391-17.2018 |
Ejemplares similares
-
Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia
por: Cui, Jiankun, et al.
Publicado: (2012) -
Two-Dimensional Zymography Differentiates Gelatinase Isoforms in Stimulated Microglial Cells and in Brain Tissues of Acute Brain Injuries
por: Chen, Shanyan, et al.
Publicado: (2015) -
Successful use of tPA for thrombolysis in COVID related ARDS: a case series
por: Goyal, Abhishek, et al.
Publicado: (2020) -
tPA or not tPA? Lysis therapy in the setting of COVID‐19 and ECMO
por: Cromartie, Anjelica, et al.
Publicado: (2022) -
Outcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tPA for Acute Ischemic Stroke
por: Darger, Bryan, et al.
Publicado: (2015)